| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 87 | 2024 | 7734 | 4.560 |
Why?
|
| Lung Neoplasms | 69 | 2024 | 11816 | 3.370 |
Why?
|
| Diagnostic Imaging | 25 | 2024 | 1179 | 3.230 |
Why?
|
| Positron-Emission Tomography | 39 | 2024 | 2210 | 2.880 |
Why?
|
| Pleural Neoplasms | 13 | 2023 | 481 | 2.650 |
Why?
|
| Pericardium | 7 | 2024 | 161 | 2.350 |
Why?
|
| Mediastinal Neoplasms | 8 | 2022 | 427 | 2.340 |
Why?
|
| Thoracic Neoplasms | 8 | 2021 | 340 | 2.130 |
Why?
|
| Mediastinum | 11 | 2022 | 276 | 1.970 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 31 | 2024 | 5465 | 1.640 |
Why?
|
| Mesothelioma | 10 | 2022 | 557 | 1.640 |
Why?
|
| Positron Emission Tomography Computed Tomography | 14 | 2024 | 858 | 1.590 |
Why?
|
| Fluorodeoxyglucose F18 | 26 | 2024 | 1253 | 1.570 |
Why?
|
| Thymus Neoplasms | 9 | 2024 | 413 | 1.470 |
Why?
|
| Neoplasm Staging | 41 | 2024 | 13880 | 1.380 |
Why?
|
| Solitary Pulmonary Nodule | 7 | 2021 | 125 | 1.380 |
Why?
|
| Multimodal Imaging | 8 | 2015 | 553 | 1.360 |
Why?
|
| Thorax | 9 | 2022 | 219 | 1.330 |
Why?
|
| Tomography, Emission-Computed | 10 | 2011 | 324 | 1.200 |
Why?
|
| Lymphadenopathy | 3 | 2022 | 91 | 1.050 |
Why?
|
| Radiopharmaceuticals | 21 | 2024 | 1335 | 1.020 |
Why?
|
| Radiography, Thoracic | 14 | 2019 | 462 | 0.960 |
Why?
|
| Lung | 27 | 2022 | 3241 | 0.930 |
Why?
|
| Mediastinal Diseases | 2 | 2022 | 58 | 0.910 |
Why?
|
| Diagnostic Errors | 7 | 2021 | 518 | 0.850 |
Why?
|
| Pulmonary Embolism | 6 | 2022 | 343 | 0.840 |
Why?
|
| Image Interpretation, Computer-Assisted | 6 | 2021 | 611 | 0.830 |
Why?
|
| Diagnosis, Differential | 26 | 2019 | 4848 | 0.820 |
Why?
|
| Fat Necrosis | 1 | 2022 | 64 | 0.790 |
Why?
|
| Humans | 166 | 2024 | 270490 | 0.780 |
Why?
|
| Lung Diseases | 6 | 2024 | 738 | 0.770 |
Why?
|
| Thymoma | 5 | 2024 | 250 | 0.660 |
Why?
|
| Heart Neoplasms | 3 | 2018 | 215 | 0.600 |
Why?
|
| Early Detection of Cancer | 4 | 2023 | 1334 | 0.590 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2022 | 360 | 0.590 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 341 | 0.580 |
Why?
|
| Radiology Information Systems | 1 | 2018 | 118 | 0.570 |
Why?
|
| Bronchial Neoplasms | 1 | 2017 | 80 | 0.570 |
Why?
|
| Neuroblastoma | 1 | 2022 | 695 | 0.570 |
Why?
|
| Bone Cements | 2 | 2015 | 49 | 0.550 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2024 | 7960 | 0.530 |
Why?
|
| Mass Screening | 4 | 2022 | 1568 | 0.520 |
Why?
|
| Radiotherapy | 5 | 2017 | 1852 | 0.520 |
Why?
|
| Heart Diseases | 1 | 2022 | 756 | 0.510 |
Why?
|
| Thoracic Diseases | 1 | 2015 | 33 | 0.500 |
Why?
|
| Lymphatic Diseases | 2 | 2013 | 130 | 0.490 |
Why?
|
| Artifacts | 10 | 2021 | 539 | 0.480 |
Why?
|
| Tomography, Spiral Computed | 3 | 2010 | 133 | 0.470 |
Why?
|
| Immunotherapy | 8 | 2024 | 3480 | 0.470 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2024 | 521 | 0.420 |
Why?
|
| Pericardial Effusion | 1 | 2013 | 124 | 0.420 |
Why?
|
| False Positive Reactions | 8 | 2015 | 361 | 0.420 |
Why?
|
| Contrast Media | 12 | 2015 | 1496 | 0.410 |
Why?
|
| Adipose Tissue, Brown | 3 | 2013 | 114 | 0.400 |
Why?
|
| Antineoplastic Agents | 9 | 2024 | 14502 | 0.400 |
Why?
|
| Lymphatic Metastasis | 12 | 2019 | 4925 | 0.390 |
Why?
|
| Dyspnea | 1 | 2015 | 425 | 0.390 |
Why?
|
| Perfusion Imaging | 1 | 2011 | 31 | 0.390 |
Why?
|
| Multidetector Computed Tomography | 3 | 2024 | 154 | 0.370 |
Why?
|
| Pneumonia | 5 | 2022 | 760 | 0.370 |
Why?
|
| Pleura | 3 | 2022 | 128 | 0.350 |
Why?
|
| Pulmonary Artery | 3 | 2020 | 522 | 0.340 |
Why?
|
| Sensitivity and Specificity | 15 | 2019 | 5122 | 0.300 |
Why?
|
| Hemorrhage | 2 | 2022 | 766 | 0.290 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2009 | 1699 | 0.290 |
Why?
|
| Vocal Cord Paralysis | 2 | 2006 | 87 | 0.280 |
Why?
|
| Esophageal Neoplasms | 8 | 2022 | 3241 | 0.280 |
Why?
|
| Middle Aged | 53 | 2022 | 89424 | 0.280 |
Why?
|
| Male | 61 | 2022 | 127456 | 0.270 |
Why?
|
| Digestive System Diseases | 2 | 2018 | 36 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2017 | 5531 | 0.260 |
Why?
|
| Lung Diseases, Fungal | 3 | 2015 | 124 | 0.260 |
Why?
|
| Adult | 45 | 2022 | 80607 | 0.260 |
Why?
|
| Mycobacterium avium | 1 | 2005 | 22 | 0.260 |
Why?
|
| Mycobacterium avium Complex | 1 | 2005 | 30 | 0.260 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2005 | 32 | 0.260 |
Why?
|
| Carcinoma, Small Cell | 1 | 2008 | 418 | 0.250 |
Why?
|
| Aged | 46 | 2021 | 72809 | 0.250 |
Why?
|
| Multiple Pulmonary Nodules | 2 | 2017 | 60 | 0.250 |
Why?
|
| Histoplasma | 1 | 2004 | 30 | 0.250 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2004 | 19 | 0.240 |
Why?
|
| Female | 59 | 2022 | 147097 | 0.240 |
Why?
|
| Lymphadenitis | 1 | 2004 | 40 | 0.240 |
Why?
|
| Radiation Injuries | 4 | 2021 | 1449 | 0.240 |
Why?
|
| Parietal Lobe | 1 | 2004 | 71 | 0.240 |
Why?
|
| Pulmonologists | 1 | 2024 | 12 | 0.240 |
Why?
|
| Histoplasmosis | 1 | 2004 | 73 | 0.240 |
Why?
|
| Hematologic Neoplasms | 4 | 2022 | 1919 | 0.240 |
Why?
|
| Head and Neck Neoplasms | 4 | 2017 | 4073 | 0.230 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2022 | 412 | 0.230 |
Why?
|
| Radiography | 8 | 2018 | 1944 | 0.230 |
Why?
|
| Epilepsy, Generalized | 1 | 2004 | 74 | 0.230 |
Why?
|
| Polytetrafluoroethylene | 1 | 2004 | 113 | 0.230 |
Why?
|
| Neoplasms | 11 | 2024 | 15696 | 0.210 |
Why?
|
| Radiologists | 3 | 2022 | 177 | 0.210 |
Why?
|
| Postoperative Complications | 5 | 2021 | 5826 | 0.210 |
Why?
|
| Pulmonary Veins | 1 | 2004 | 182 | 0.200 |
Why?
|
| Hemosiderin | 1 | 2021 | 6 | 0.200 |
Why?
|
| Methemoglobin | 1 | 2021 | 9 | 0.200 |
Why?
|
| Image Enhancement | 2 | 2007 | 568 | 0.200 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2017 | 1261 | 0.200 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2021 | 38 | 0.200 |
Why?
|
| Incidental Findings | 2 | 2018 | 285 | 0.190 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 2352 | 0.190 |
Why?
|
| Necrosis | 1 | 2022 | 598 | 0.190 |
Why?
|
| ErbB Receptors | 3 | 2018 | 2329 | 0.180 |
Why?
|
| Laryngeal Neoplasms | 1 | 2004 | 519 | 0.180 |
Why?
|
| Bevacizumab | 4 | 2018 | 947 | 0.180 |
Why?
|
| Carotid Arteries | 1 | 2021 | 255 | 0.180 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2021 | 166 | 0.170 |
Why?
|
| Angiography | 2 | 2022 | 361 | 0.170 |
Why?
|
| Fibroma | 1 | 2000 | 88 | 0.170 |
Why?
|
| Radiographic Image Enhancement | 4 | 2016 | 406 | 0.170 |
Why?
|
| Tuberculosis | 1 | 2005 | 589 | 0.160 |
Why?
|
| Airway Obstruction | 1 | 2021 | 269 | 0.160 |
Why?
|
| Mycoses | 1 | 2022 | 386 | 0.160 |
Why?
|
| Leukemia, Lymphoid | 1 | 2019 | 280 | 0.150 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2018 | 54 | 0.150 |
Why?
|
| Arginine Vasopressin | 1 | 2018 | 60 | 0.150 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2018 | 390 | 0.150 |
Why?
|
| Machine Learning | 1 | 2021 | 356 | 0.150 |
Why?
|
| Colonic Diseases | 1 | 1998 | 74 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 608 | 0.150 |
Why?
|
| Thyroid Nodule | 1 | 2018 | 93 | 0.140 |
Why?
|
| Legionellosis | 1 | 2016 | 17 | 0.140 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2016 | 14 | 0.140 |
Why?
|
| Opportunistic Infections | 1 | 2018 | 226 | 0.140 |
Why?
|
| Vascular Diseases | 2 | 2016 | 258 | 0.140 |
Why?
|
| Glucose-6-Phosphate | 2 | 2006 | 13 | 0.140 |
Why?
|
| Blood Vessels | 2 | 2015 | 218 | 0.140 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2016 | 27 | 0.140 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2016 | 34 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2022 | 6769 | 0.140 |
Why?
|
| Lymph Nodes | 4 | 2018 | 3033 | 0.130 |
Why?
|
| Adenocarcinoma | 6 | 2014 | 7901 | 0.130 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 727 | 0.130 |
Why?
|
| Fiducial Markers | 1 | 2016 | 96 | 0.130 |
Why?
|
| Aged, 80 and over | 19 | 2021 | 30768 | 0.130 |
Why?
|
| Retrospective Studies | 22 | 2023 | 39468 | 0.130 |
Why?
|
| Hyperparathyroidism | 2 | 2006 | 97 | 0.130 |
Why?
|
| Esophagus | 2 | 2018 | 557 | 0.130 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 210 | 0.130 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 133 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2371 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 421 | 0.120 |
Why?
|
| Pneumonectomy | 2 | 2018 | 871 | 0.120 |
Why?
|
| Enoxaparin | 1 | 2015 | 73 | 0.120 |
Why?
|
| Muscle, Skeletal | 3 | 2007 | 1328 | 0.120 |
Why?
|
| Gonadal Disorders | 1 | 2013 | 8 | 0.120 |
Why?
|
| Urologic Diseases | 1 | 2014 | 78 | 0.120 |
Why?
|
| Muscle, Striated | 1 | 2013 | 13 | 0.120 |
Why?
|
| Leukemia, Myeloid | 1 | 2019 | 964 | 0.110 |
Why?
|
| Thrombosis | 1 | 2020 | 812 | 0.110 |
Why?
|
| Radiosurgery | 1 | 2023 | 1369 | 0.110 |
Why?
|
| Heart | 3 | 2018 | 1255 | 0.110 |
Why?
|
| Warfarin | 1 | 2015 | 159 | 0.110 |
Why?
|
| Empyema | 1 | 2013 | 28 | 0.110 |
Why?
|
| Respiratory Tract Fistula | 1 | 2013 | 35 | 0.110 |
Why?
|
| Bronchial Fistula | 1 | 2013 | 37 | 0.110 |
Why?
|
| Pulmonary Edema | 1 | 2013 | 78 | 0.110 |
Why?
|
| Pleural Diseases | 1 | 2013 | 58 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2016 | 335 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2018 | 1856 | 0.110 |
Why?
|
| Research Design | 1 | 2010 | 1598 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 1377 | 0.110 |
Why?
|
| Neoplasm Metastasis | 5 | 2018 | 5238 | 0.100 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 905 | 0.100 |
Why?
|
| Thoracotomy | 1 | 2013 | 225 | 0.100 |
Why?
|
| Colonic Neoplasms | 2 | 2007 | 1429 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1890 | 0.100 |
Why?
|
| United States | 4 | 2022 | 16312 | 0.100 |
Why?
|
| Risk Factors | 7 | 2019 | 18238 | 0.100 |
Why?
|
| Follow-Up Studies | 8 | 2023 | 15189 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2017 | 935 | 0.100 |
Why?
|
| Smoking | 1 | 2010 | 2523 | 0.100 |
Why?
|
| Vulvar Neoplasms | 1 | 2013 | 235 | 0.100 |
Why?
|
| Carcinoma | 1 | 2022 | 2601 | 0.090 |
Why?
|
| Whole Body Imaging | 1 | 2011 | 114 | 0.090 |
Why?
|
| Pneumonia, Lipid | 1 | 2010 | 5 | 0.090 |
Why?
|
| Thyroid Gland | 2 | 2018 | 358 | 0.090 |
Why?
|
| Tissue Extracts | 1 | 2010 | 48 | 0.090 |
Why?
|
| Prognosis | 8 | 2022 | 22229 | 0.090 |
Why?
|
| Combined Modality Therapy | 7 | 2021 | 9002 | 0.090 |
Why?
|
| Treatment Outcome | 13 | 2021 | 34185 | 0.090 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2010 | 47 | 0.090 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2009 | 21 | 0.090 |
Why?
|
| Quality Control | 2 | 2017 | 461 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 396 | 0.090 |
Why?
|
| Iatrogenic Disease | 2 | 2014 | 182 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2017 | 1198 | 0.090 |
Why?
|
| Reproducibility of Results | 6 | 2021 | 6192 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2011 | 5030 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2015 | 855 | 0.080 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2008 | 74 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1313 | 0.080 |
Why?
|
| Zygomycosis | 1 | 2008 | 30 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 4884 | 0.080 |
Why?
|
| Fusarium | 1 | 2008 | 51 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2014 | 2425 | 0.080 |
Why?
|
| Subtraction Technique | 2 | 2006 | 142 | 0.080 |
Why?
|
| Survival Rate | 6 | 2013 | 12429 | 0.080 |
Why?
|
| Parathyroidectomy | 2 | 2006 | 208 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 1569 | 0.080 |
Why?
|
| Adipose Tissue | 2 | 2006 | 775 | 0.070 |
Why?
|
| Adolescent | 6 | 2018 | 32276 | 0.070 |
Why?
|
| Pyridines | 2 | 2017 | 1289 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 597 | 0.070 |
Why?
|
| Observer Variation | 4 | 2017 | 708 | 0.070 |
Why?
|
| Respiration | 2 | 2006 | 452 | 0.070 |
Why?
|
| Liver | 2 | 2022 | 2989 | 0.070 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2006 | 89 | 0.070 |
Why?
|
| Hyperventilation | 1 | 2006 | 19 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2012 | 712 | 0.070 |
Why?
|
| Acne Vulgaris | 1 | 2006 | 46 | 0.070 |
Why?
|
| Respiratory Muscles | 1 | 2006 | 27 | 0.070 |
Why?
|
| Pleurodesis | 1 | 2006 | 71 | 0.070 |
Why?
|
| Arteriovenous Fistula | 1 | 2007 | 102 | 0.070 |
Why?
|
| Ulcer | 1 | 2006 | 76 | 0.070 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2006 | 70 | 0.070 |
Why?
|
| Proton Therapy | 1 | 2016 | 1598 | 0.070 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 75 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2024 | 10254 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2010 | 16258 | 0.060 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 247 | 0.060 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2004 | 23 | 0.060 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2012 | 109 | 0.060 |
Why?
|
| Kyphosis | 1 | 2004 | 44 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 2006 | 397 | 0.060 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2004 | 63 | 0.060 |
Why?
|
| Pancreatitis | 2 | 2020 | 279 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2005 | 184 | 0.060 |
Why?
|
| Sesquiterpenes | 1 | 2004 | 71 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2023 | 13274 | 0.060 |
Why?
|
| Injections, Intralesional | 1 | 2004 | 163 | 0.060 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2005 | 142 | 0.060 |
Why?
|
| Mass Chest X-Ray | 1 | 2003 | 4 | 0.060 |
Why?
|
| Piperidines | 1 | 2009 | 1067 | 0.060 |
Why?
|
| Immunocompromised Host | 2 | 2022 | 709 | 0.060 |
Why?
|
| Spine | 1 | 2004 | 307 | 0.050 |
Why?
|
| Reference Values | 1 | 2005 | 1129 | 0.050 |
Why?
|
| Biopsy, Needle | 3 | 2018 | 1395 | 0.050 |
Why?
|
| Organoplatinum Compounds | 1 | 2005 | 706 | 0.050 |
Why?
|
| Seasons | 1 | 2023 | 353 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 1354 | 0.050 |
Why?
|
| Ischemic Attack, Transient | 1 | 2021 | 59 | 0.050 |
Why?
|
| Public Opinion | 1 | 2022 | 89 | 0.050 |
Why?
|
| Ultrasonography | 3 | 2009 | 1925 | 0.050 |
Why?
|
| Thyroiditis | 1 | 2020 | 19 | 0.050 |
Why?
|
| Lymphoma | 1 | 2010 | 1495 | 0.050 |
Why?
|
| Biopsy | 3 | 2014 | 3486 | 0.050 |
Why?
|
| Indoles | 1 | 2006 | 1021 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2023 | 347 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 3 | 2007 | 2496 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2007 | 959 | 0.050 |
Why?
|
| Adrenal Gland Diseases | 1 | 2020 | 72 | 0.040 |
Why?
|
| Pericarditis | 1 | 2020 | 63 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 1470 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2005 | 1269 | 0.040 |
Why?
|
| Mouth | 1 | 2021 | 123 | 0.040 |
Why?
|
| Hepatitis | 1 | 2020 | 93 | 0.040 |
Why?
|
| Myocardium | 1 | 2006 | 1335 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2010 | 180 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 2020 | 113 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2007 | 1347 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 4052 | 0.040 |
Why?
|
| Encephalitis | 1 | 2020 | 146 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2010 | 242 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2010 | 302 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 673 | 0.040 |
Why?
|
| Pneumothorax | 1 | 2000 | 162 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 387 | 0.040 |
Why?
|
| Colitis, Ischemic | 1 | 1998 | 5 | 0.040 |
Why?
|
| Diverticulitis, Colonic | 1 | 1998 | 11 | 0.040 |
Why?
|
| Myocarditis | 1 | 2020 | 197 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 7701 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2006 | 2374 | 0.040 |
Why?
|
| Prevalence | 2 | 2018 | 3396 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 2273 | 0.040 |
Why?
|
| Liver Diseases | 2 | 2014 | 594 | 0.040 |
Why?
|
| Mutation | 1 | 2018 | 15577 | 0.040 |
Why?
|
| Quinazolines | 2 | 2017 | 934 | 0.040 |
Why?
|
| Colitis | 1 | 2020 | 338 | 0.040 |
Why?
|
| Catheterization, Central Venous | 1 | 2000 | 365 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 2394 | 0.040 |
Why?
|
| Ascites | 1 | 1998 | 210 | 0.040 |
Why?
|
| Doxorubicin | 2 | 2004 | 3059 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2004 | 2055 | 0.040 |
Why?
|
| Legionella | 1 | 2016 | 18 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2000 | 734 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 2858 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2010 | 1025 | 0.030 |
Why?
|
| Ireland | 1 | 2015 | 27 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2006 | 1701 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2364 | 0.030 |
Why?
|
| Metals | 1 | 2016 | 156 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 5292 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 1998 | 275 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2018 | 9323 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 326 | 0.030 |
Why?
|
| Foreign Bodies | 1 | 2016 | 143 | 0.030 |
Why?
|
| Intestine, Small | 1 | 1998 | 514 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 2 | 2007 | 5105 | 0.030 |
Why?
|
| Child | 3 | 2022 | 30136 | 0.030 |
Why?
|
| Crohn Disease | 1 | 1998 | 367 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2005 | 1888 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 1224 | 0.030 |
Why?
|
| Splenic Diseases | 1 | 2014 | 60 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 302 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 5114 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2014 | 16760 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 2014 | 126 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 5028 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 3836 | 0.030 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2012 | 17 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 2007 | 4995 | 0.030 |
Why?
|
| Stroke | 1 | 2021 | 1198 | 0.030 |
Why?
|
| Abdomen | 1 | 2014 | 337 | 0.030 |
Why?
|
| Pelvis | 1 | 2014 | 380 | 0.030 |
Why?
|
| Ileus | 1 | 2012 | 31 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2008 | 949 | 0.030 |
Why?
|
| Neoplasm, Residual | 2 | 2009 | 1716 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 469 | 0.020 |
Why?
|
| Esophagectomy | 2 | 2007 | 948 | 0.020 |
Why?
|
| Sarcoma | 1 | 2002 | 1830 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 1131 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2018 | 7164 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 2980 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 1314 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2005 | 1410 | 0.020 |
Why?
|
| Respiratory Aspiration | 1 | 2010 | 31 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 3518 | 0.020 |
Why?
|
| Cartilage | 1 | 2010 | 125 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 4775 | 0.020 |
Why?
|
| Algorithms | 1 | 2021 | 3983 | 0.020 |
Why?
|
| Gastroenteritis | 1 | 2012 | 310 | 0.020 |
Why?
|
| Melanoma | 1 | 2006 | 5444 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 1807 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2017 | 1517 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 1991 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 804 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 5916 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2009 | 745 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2008 | 95 | 0.020 |
Why?
|
| Neutropenia | 1 | 2012 | 987 | 0.020 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2009 | 199 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2012 | 3362 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2006 | 35 | 0.020 |
Why?
|
| Back | 1 | 2006 | 45 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 165 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2006 | 122 | 0.020 |
Why?
|
| Biological Products | 1 | 2010 | 311 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2009 | 699 | 0.020 |
Why?
|
| HIV Infections | 1 | 2019 | 2219 | 0.020 |
Why?
|
| Young Adult | 2 | 2018 | 22102 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2009 | 556 | 0.020 |
Why?
|
| Parathyroid Glands | 1 | 2006 | 127 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 658 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2009 | 1314 | 0.020 |
Why?
|
| Disease Progression | 2 | 2009 | 6888 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 326 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 4875 | 0.020 |
Why?
|
| Bronchography | 1 | 2004 | 25 | 0.020 |
Why?
|
| Parathyroid Neoplasms | 1 | 2006 | 186 | 0.020 |
Why?
|
| Cyclohexanes | 1 | 2004 | 39 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 2006 | 304 | 0.020 |
Why?
|
| Thoracoscopy | 1 | 2005 | 103 | 0.020 |
Why?
|
| Heart Failure | 1 | 1998 | 2658 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2010 | 2662 | 0.010 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2005 | 171 | 0.010 |
Why?
|
| Thymectomy | 1 | 2004 | 78 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2005 | 332 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2009 | 2018 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 696 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 889 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 573 | 0.010 |
Why?
|
| Liposomes | 1 | 2005 | 690 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2006 | 1569 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 4385 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 1583 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 997 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 3960 | 0.010 |
Why?
|
| Exons | 1 | 2006 | 1351 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2007 | 589 | 0.010 |
Why?
|
| Carboplatin | 1 | 2004 | 844 | 0.010 |
Why?
|
| Subclavian Vein | 1 | 2000 | 35 | 0.010 |
Why?
|
| Thoracostomy | 1 | 2000 | 45 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6269 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2006 | 1564 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2006 | 3070 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 2478 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2004 | 829 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 10092 | 0.010 |
Why?
|
| Catheterization | 1 | 2000 | 433 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 2456 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 3143 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2000 | 579 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2005 | 2616 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2002 | 909 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 2002 | 948 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 4442 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 9064 | 0.010 |
Why?
|